Novel chloropyridazine hybrids as promising anticancer agents acting by apoptosis induction and PARP-1 inhibition through a molecular hybridization strategy.
Trimethoxy derivatives 5f (IC50 = 1.50 μM) and 6f (IC50 = 1.15 μM) demonstrated higher COX-2 inhibitory activity than celecoxib. Also, they showed the highest inhibition of NO, TNF-α, IL-6, and PGE-2 production in LPS-induced RAW264.7 macrophages.
This study reports the design, synthesis, and biological evaluation of a novel series of 3-oxo-2,3-dihydropyridazine derivatives for selective inhibition of ITK, with potential application in T-cell leukemia treatment.
Full control of the molecular orientation of planar molecules is achieved by means of electric fields designed using quantum optimal control theory.
New series of triazolo[4,3-b]pyridazine derivatives were created. Compounds 4a and 4g demonstrated extensive antiproliferative activity on various cell lines. Compound 4g displayed higher dual inhibition on c-Met and Pim-1.